Начало・Списък с акции・Vericel Corp

Vericel Corp

Отворен

СекторЗдравеопазване

43.99 -1.1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

43.27

Максимум

44.91

Ключови измерители
By Trading Economics
Приходи	13M 6.3M
Продажби	9M 77M
P/E Средно за сектора	93.511 57.002
EPS	0.04
Марж на печалбата	8.136
Служители	398
EBITDA	8.5M 5.6M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+38.08% upside

Дивиденти
By Acuity
Следващи печалби	5.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-64M 2.3B
Предишно отваряне	45.09
Предишно затваряне	43.99

Настроения в новините

By Acuity

100%

325 / 340 Класиране в Healthcare

Vericel Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.08.2026 г., 19:43 ч. UTC

Vericel Corp shares are lower today, reflecting ongoing weakness below the 20-day moving average and near the lower end of their one-month range.

11.08.2026 г., 19:46 ч. UTC

News

Vericel Corp shares are higher as analysts maintain a "Moderate Buy" consensus, with HC Wainwright's target at $70 and Truist raising its target to $58.

10.08.2026 г., 19:46 ч. UTC

Correlated Moves

Vericel Corp shares are lower today, reflecting a broader market decline and volatility amid uncertainty over the Federal Reserve's interest rate policy.

7.08.2026 г., 19:16 ч. UTC

Correlated Moves

Vericel Corp's shares rise, supported by gains in the ARK Genomic Revolution ETF and Russell 2000 Index, despite earlier fluctuations in trading.

6.08.2026 г., 19:26 ч. UTC

Correlated Moves

Vericel Corp shares declined during Thursday's session, tracking broader market trends. The stock remains near the lower end of its one-month trading range.

5.08.2026 г., 19:26 ч. UTC

Correlated Moves

Vericel Corp shares are lower today, reflecting broader market trends as the Russell 2000 Index declines. The stock remains below its 20-day moving average.

3.08.2026 г., 20:03 ч. UTC

Correlated Moves

Vericel Corp shares are advancing, supported by significant gains in the broader market and major tech stocks, contributing to positive investor sentiment.

31.07.2026 г., 20:02 ч. UTC

Correlated Moves

Vericel Corp's price is lower today, influenced by declines in the Biotechnology sub-sector and a falling Russell 2000 Index.

30.07.2026 г., 20:36 ч. UTC

Correlated Moves

Vericel Corp shares gained in after-market trading, aligning with a rising Russell 2000 Index. The stock remains above its 20-day moving average.

29.07.2026 г., 19:27 ч. UTC

Correlated Moves

Vericel Corp shares declined during Wednesday's session, continuing a downward trend since Tuesday's close, amid broader market weakness reflected in the Russell 2000 Index.

28.07.2026 г., 21:02 ч. UTC

Vericel Corp shares are lower in after-market trading, reflecting broader market caution amid declines in the Nikkei 225 Index and technology sector concerns.

27.07.2026 г., 20:31 ч. UTC

Vericel Corp shares declined during after-market hours amid unusual selling pressure. The stock remains below its 20-day moving average with no specific news identified.

24.07.2026 г., 19:46 ч. UTC

Correlated Moves

Vericel Corp reported first-quarter revenue of $39.2 million, missing estimates. Shares are lower amid broader market declines affecting small-cap biotechnology stocks.

22.07.2026 г., 20:13 ч. UTC

Vericel Corp shares are trading higher in after-market hours, influenced by broader market volatility amid rising crude oil prices and geopolitical tensions.

21.07.2026 г., 14:31 ч. UTC

Vericel Corp shares are higher, supported by overall market momentum and a recovery in Asian markets, particularly the Nikkei 225 Index.

20.07.2026 г., 17:46 ч. UTC

Correlated Moves

Vericel Corp shares are lower today, aligning with a decline in the ARK Genomic Revolution ETF and the Russell 2000 Index.

Сравнение с други в отрасъла

Ценова промяна

Vericel Corp Прогноза

Ценова цел

By TipRanks

38.08% нагоре

12-месечна прогноза

Среден 61.5 USD 38.08%

Висок 72 USD

Нисък 58 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Vericel Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Vericel Corp през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vericel Corp

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.